CGEM — Cullinan Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1789972 ·
Last close
$9.27
Market Cap
$602.14M
52W High
$23.19
52W Low
$8.23
ADV30
868,966
Next earnings
2026-11-10
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -52,600,000 -49,388,000 322,559,000 88,260,000 41,275,000
Jun 2026 0 — -57,254,000 -53,704,000 363,787,000 78,640,000 42,033,000
Mar 2026 0 — -53,697,000 -49,661,000 402,984,000 75,081,000 36,812,000
Dec 2025 0 — -55,259,000 -50,713,000 448,374,000 88,332,000 39,644,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-165,455,000
Investing CF
$147,123,000
Financing CF
$3,257,000
CapEx
$-11,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.07
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-740,872,000
Inventory
—
Receivables
—
ST Investments
$201,313,000
EBIT TTM
$-218,810,000
Pretax Income TTM
$-203,466,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -241,648,000 -219,879,000 448,374,000 39,644,000 408,730,000 -175,750,000
Dec 2024 0 -196,919,000 -167,383,000 621,824,000 31,496,000 590,328,000 -145,303,000
Dec 2023 0 -190,649,000 -153,162,000 484,182,000 30,287,000 453,703,000 -134,275,000
Dec 2022 0 -132,137,000 111,214,000 561,117,000 26,088,000 535,029,000 -126,664,000

TTM Snapshot

Revenues TTM
$17,454,000
NetIncome TTM
$-204,688,000
OpCashFlow TTM
—
Assets (Latest)
$363,787,000
Forward EPS
$-2.36

Max Pain — expiry 2027-01-15

max pain strike: $14.00 · spot: $9.01 · call oi: 3,818 · put oi: 538

Peers — same industry

TickerNameMarket CapLastDaily %
FDMT 4D Molecular Therapeutics, Inc. $608.33M $10.79 —
DBVT DBV Technologies S.A. $627.78M $9.99 —
SRZN Surrozen, Inc./DE $571.47M $29.98 —
SANA Sana Biotechnology, Inc. $563.31M $1.88 —
IAM Iambic Therapeutics, Inc. $674.04M $14.22 —

News headlines (Yahoo Finance, 1h cache)

New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
2026-11-12 21:30 · Yahoo
Cullinan Therapeutics: Q3 Earnings Snapshot
2026-11-10 12:15 · Yahoo
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-10 12:00 · Yahoo
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
2026-11-09 15:00 · Yahoo
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
2026-11-08 15:30 · Yahoo
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
2026-11-04 14:14 · Yahoo
Cullinan Therapeutics (CGEM) Wins Trial Clearance, Is The Upside Already Priced In?
2026-10-31 19:12 · Yahoo
Cullinan Therapeutics (CGEM) Stock May Be Fully Priced Following Trial Progress
2026-10-29 15:16 · Yahoo
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?
2026-10-29 12:55 · Yahoo
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
2026-10-27 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.